Revolutionary therapy treats Hunter syndrome for first time
A world-first therapy has provided an unprecedented step towards treating the devastating condition Hunter syndrome.
Researchers at the University of Manchester treated a three-year-old boy, Ollie Chu, with a stem cell gene therapy treatment developed by the university. Several months on from the procedure performed in February, Ollie has recovered from the transplant with encouraging signs of progress.
Hunter syndrome is a devastating, life-limited inherited condition, also known as mucopolysaccharidosis type II (MPS II). The condition can be life-threatening, with life expectancy typically between 10 and 20 years.
Hunter syndrome is caused by an error in a gene, meaning those living with the condition cannot produce an important enzyme which breaks down complex sugar molecules. These sugars build up in organs and tissues, leading to joint stiffness, hearing loss, breathing and heart problems, developmental delays and cognitive decline.
The innovative procedure involved a one-off gene therapy removing Ollie’s stem cells, replacing the faulty gene and re-injecting the modified cells into the patient. These stem cells can produce high levels of the missing enzyme and also reach the brain.
“For many years, we have performed bone marrow transplant for children with Hunter syndrome and similar illnesses,” said Professor Rob Wynn, Consultant Paediatric Haematologist and Director of Paediatric Bone Marrow Transplant Programme at RMCH and joint clinical lead.
“However, these are difficult procedures that can only deliver as much enzyme as the donor’s blood naturally has.
“Gene therapy is not only safer and more effective, but it enables us to use the child’s own cells which cuts out the need to find a donor, and means we can produce more enzyme for the patient.
“The principles of using gene therapy of blood cells to treat patients with this disease can be applied to many other conditions which offers exciting prospects for patients and healthcare professionals. Our medicine is becoming safer, and better, and that can only be a good thing!”
Treatment for life-threatening disease is ‘exciting development’
The only licensed drug that can currently help to improve life for children with Hunter syndrome is Elaprase, a weekly enzyme replacement therapy that takes approximately three hours which children must take for their whole life.
Approximately 50 patients in the UK receive Elaprase, which costs around £375,000 ($493,000) a year per patient. The drug can reduce mobility and organ problems but cannot improve mental decline.
However, the clinical study, delivered at Royal Manchester Children’s Hospital (RMCH) in collaboration with the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, offers hope for a new treatment.
Professor Simon Jones, Consultant in Paediatric Inherited Metabolic Disease at the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital and joint study lead, noted that the gene therapy treatment meant that Ollie was no longer receiving Elaprase infusions.
“I have worked in researching treatments for children with rare genetic diseases for over twenty years and I have sadly seen many children lose their lives to these devastating conditions. This is a truly exciting development which could lead the way for treating similar genetic conditions and bring hope to other families.”
Bruno Quinney, Content Team, DDW
